Nuvasive Inc NUVA
We take great care to ensure that the data presented and summarized in this overview for NUVASIVE INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NUVA
View all-
Rothschild & CO Asset Management Us Inc. New York, NY66KShares$00.04% of portfolio
-
Walthausen & Co., LLC Malta, NY25.3KShares$00.92% of portfolio
-
Eaton Vance Management Boston, MA17.2KShares$00.0% of portfolio
-
Pictet Asset Management Sa Geneva 73, V86.27KShares$00.0% of portfolio
-
First Capital Advisors Group, Llc. Little Silver, NJ487Shares$00.01% of portfolio
-
Wipfli Financial Advisors Llc,469Shares$00.0% of portfolio
-
Piershale Financial Group, Inc.50Shares$00.0% of portfolio
-
American Portfolios Advisors Holbrook, NY14Shares$00.0% of portfolio
-
Fieldpoint Private Securities, LLC0Shares$00.0% of portfolio
Latest Institutional Activity in NUVA
Top Purchases
Top Sells
About NUVA
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary implant device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
Insider Transactions at NUVA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 01
2023
|
Leslie V Norwalk Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,095
-100.0%
|
-
|
Sep 01
2023
|
R Scott Huennekens Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,360
-100.0%
|
-
|
Sep 01
2023
|
Siddhartha Kadia Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,739
-100.0%
|
-
|
Sep 01
2023
|
Nathaniel Sisitsky SVP & General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
22,423
-100.0%
|
-
|
Sep 01
2023
|
Dale A. Wolf SVP, Global Operations |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,943
-100.0%
|
-
|
Sep 01
2023
|
Vickie L Capps Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,000
-100.0%
|
-
|
Sep 01
2023
|
James Christopher Barry Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
72,997
-100.0%
|
-
|
Sep 01
2023
|
Michael Farrington SVP, People and Culture |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,117
-100.0%
|
-
|
Sep 01
2023
|
Matthew K Harbaugh EVP and CFO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,081
-100.0%
|
-
|
Mar 01
2023
|
Michael Farrington SVP, People and Culture |
SELL
Payment of exercise price or tax liability
|
Direct |
776
-19.93%
|
$32,592
$42.67 P/Share
|
Mar 01
2023
|
Michael Farrington SVP, People and Culture |
BUY
Exercise of conversion of derivative security
|
Direct |
1,905
+32.86%
|
-
|
Mar 01
2023
|
Dale A. Wolf SVP, Global Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
1,428
-13.77%
|
$59,976
$42.67 P/Share
|
Mar 01
2023
|
Dale A. Wolf SVP, Global Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
4,572
+30.6%
|
-
|
Mar 01
2023
|
Marc W. Rosenbaum Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
745
-6.05%
|
$31,290
$42.67 P/Share
|
Mar 01
2023
|
Marc W. Rosenbaum Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,829
+12.92%
|
-
|
Mar 01
2023
|
James Christopher Barry Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,505
-13.62%
|
$483,210
$42.67 P/Share
|
Mar 01
2023
|
James Christopher Barry Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
34,284
+28.86%
|
-
|
Mar 01
2023
|
Matthew K Harbaugh EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,526
-25.1%
|
$148,092
$42.67 P/Share
|
Mar 01
2023
|
Matthew K Harbaugh EVP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,190
+46.46%
|
-
|
Mar 01
2023
|
Nathaniel Sisitsky SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,976
-8.29%
|
$82,992
$42.67 P/Share
|